Gene therapy: A promising approach for neuroprotection in Parkinson’s disease?

Frontiers in Neuroanatomy

Volumn 10, Issue DEC, 2016, Pages

  Valdés, Pamela ^a   Schneider, Bernard L ^a  

^a EPFL   (Switzerland)

Author keywords

Autophagy; Gene therapy; Mitochondria; Neuroprotection; Neurotrophic factors; Parkinson s disease; Risk factors

Indexed keywords

CRISPR ASSOCIATED PROTEIN; PARVOVIRUS VECTOR;

ARTICLE; AUTOPHAGY; DNA MODIFICATION; ENDOPLASMIC RETICULUM STRESS; GENE THERAPY; HUMAN; METABOLIC ACTIVITY ASSAY; NEUROPROTECTION; PARKINSON DISEASE; PROTEIN EXPRESSION; RISK FACTOR; UNFOLDED PROTEIN RESPONSE;

EID: 85007425309     PISSN: None     EISSN: 16625129     Source Type: Journal    
DOI: 10.3389/fnana.2016.00123     Document Type: Article

References (59)

1. Awad, O., Sarkar, C., Panicker, L. M., Miller, D., Zeng, X., Sgambato, J. A., et al. (2015). Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum. Mol. Genet. 24, 5775-5788. doi: 10. 1093/hmg/ddv297.
2. Azzouz, M., Martin-Rendon, E., Barber, R. D., Mitrophanous, K. A., Carter, E. E., Rohll, J. B., et al. (2002). Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase and GTP cyclohydrolase I induces sustained transgene expression, dopamine production and functional improvement in a rat model of Parkinson’s disease. J. Neurosci. 22, 10302-10312.
3. Back, S., Peranen, J., Galli, E., Pulkkila, P., Lonka-Nevalaita, L., Tamminen, T., et al. (2013). Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson’s disease. Brain Behav. 3, 75-88. doi: 10.1002/ brb3.117.
4. Burre, J. (2015). The synaptic function of a-synuclein. J. Parkinsons Dis. 5, 699-713. doi: 10.3233/JPD-150642.
5. Chung, C. Y., Khurana, V., Auluck, P. K., Tardiff, D. F., Mazzulli, J. R., Soldner, F., et al. (2013). Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342, 983-987. doi: 10.1126/science.1245296.
6. Ciron, C., Lengacher, S., Dusonchet, J., Aebischer, P., and Schneider, B. L. (2012). Sustained expression of PGC-1 a in the rat nigrostriatal system selectively impairs dopaminergic function. Hum. Mol. Genet. 21, 1861-1876. doi: 10. 1093/hmg/ddr618.
7. Ciron, C., Zheng, L., Bobela, W., Knott, G. W., Leone, T. C., Kelly, D. P., et al. (2015). PGC-1 a activity in nigral dopamine neurons determines vulnerability to a-synuclein. Acta Neuropathol. Commun. 3:16. doi: 10.1186/s40478-015-0200-8.
8. Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., et al. (2006). Drosophila pink1 is required for mitochondrial function and interacts geneticallywith parkin. Nature 441, 1162-1166. doi: 10.1038/nature04779.
9. Clark, J., Silvaggi, J. M., Kiselak, T., Zheng, K., Clore, E. L., Dai, Y., et al. (2012). Pgc-1 a overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PLoS One 7:e48925. doi: 10. 1371/journal.pone.0048925.
10. Collier, T. J., Redmond, D. E. Jr., Steece-Collier, K., Lipton, J. W., and Manfredsson, F. P. (2016). Is α-synuclein loss-of-function a contributor to parkinsonian pathology? Evidence from non-human primates. Front. Neurosci. 10:12. doi: 10.3389/fnins.2016.00012.
11. Coune, P. G., Schneider, B. L., and Aebischer, P. (2012). Parkinson’s disease: gene therapies. Cold Spring Harb. Perspect. Med. 2:a009431. doi: 10. 1101/cshperspect.a009431.
12. Decressac, M., and Bjorklund, A. (2013). TFEB: pathogenic role and therapeutic target in Parkinson disease. Autophagy 9, 1244-1246. doi: 10.4161/auto.25044.
13. Decressac, M., Kadkhodaei, B., Mattsson, B., Laguna, A., Perlmann, T., and Bjorklund, A. (2012). a-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl. Med. 4:163ra156. doi: 10.1126/scitranslmed.3004676.
14. Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., and Bjorklund, A. (2013). TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. Acad. Sci. U S A 110, E1817-E1826. doi: 10.1073/pnas.1305623110.
15. Decressac, M., Ulusoy, A., Mattsson, B., Georgievska, B., Romero-Ramos, M., Kirik, D., et al. (2011). GDNFfails to exert neuroprotection in a rat α-synuclein model of Parkinson’s disease. Brain 134, 2302-2311. doi: 10.1093/brain/awr149.
16. Gorbatyuk, O. S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A. S., Sullivan, L. F., et al. (2010). In vivo RNAi-mediated α-synuclein silencinginduces nigrostriatal degeneration. Mol. Ther. 18, 1450-1457. doi: 10.1038/mt.2010.115.
17. Gorbatyuk, M. S., Shabashvili, A., Chen, W., Meyers, C., Sullivan, L. F., Salganik, M., et al. (2012). Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. Mol. Ther. 20, 1327-1337. doi: 10.1038/mt.2012.28.
18. Gully, J. C., Sergeyev, V. G., Bhootada, Y., Mendez-Gomez, H., Meyers, C. A., Zolotukhin, S., et al. (2016). Up-regulation of activating transcription factor 4 induces severe loss of dopamine nigral neurons in a rat model ofParkinson’s disease. Neurosci. Lett. 627, 36-41. doi: 10.1016/j.neulet.2016.05.039.
19. Hernandez, D. G., Reed, X., and Singleton, A. B. (2016). Genetics in Parkinson disease: mendelian versus non-mendelian inheritance. J. Neurochem. 139, 59-74. doi: 10.1111/jnc.13593.
20. Khodr, C. E., Becerra, A., Han, Y., and Bohn, M. C. (2014). Targeting α-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res. 1550, 47-60. doi: 10.1016/j.brainres. 2014.01.010.
21. Khodr, C. E., Sapru, M. K., Pedapati, J., Han, Y., West, N. C., Kells, A. P., et al. (2011). An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson’s disease, but displays toxicity in dopamine neurons. Brain Res. 1395, 94-107. doi: 10.1016/j.brainres.2011.04.036.
22. Kim, D. K., Lim, H. S., Kawasaki, I., Shim, Y. H., Vaikath, N. V., El-Agnaf, O. M., et al. (2016). Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. Autophagy 12, 1849-1863. doi: 10.1080/15548627.2016.1207014.
23. Klingelhoefer, L., and Reichmann, H. (2015). Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. Nat. Rev. Neurol. 11, 625-636. doi: 10.1038/nrneurol.2015.197.
24. Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models ofParkinson’s disease. Science 290, 767-773. doi: 10. 1126/science.290.5492.767.
25. Lindahl, M., Saarma, M., and Lindholm, P. (2016). Unconventional neurotrophic factors CDNF and MANF: structure, physiological functions and therapeutic potential. Neurobiol. Dis. doi: 10.1016/j.nbd.2016.07.009 [Epub ahead of print].
26. Lindholm, P., Voutilainen, M. H., Lauren, J., Peranen, J., Leppanen, V. M., Andressoo, J. O., et al. (2007). Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448, 73-77. doi: 10. 1038/nature05957.
27. Lo Bianco, C., Deglon, N., Pralong, W., and Aebischer, P. (2004a). Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson’s disease. Neurobiol. Dis. 17, 283-289. doi: 10.1016/j.nbd.2004. 06.008.
28. Lo Bianco, C., Schneider, B. L., Bauer, M., Sajadi, A., Brice, A., Iwatsubo, T., et al. (2004b). Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson’s disease. Proc. Natl. Acad. Sci. U S A 101, 17510-17515. doi: 10.1073/pnas.0405313101.
29. Lohmann, E., Periquet, M., Bonifati, V., Wood, N. W., De Michele, G., Bonnet, A. M., et al. (2003). How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 54, 176-185. doi: 10.1002/ana.10613.
30. Löw, K., Aebischer, P., and Schneider, B. L. (2013). Direct and retrograde transduction of nigral neurons with AAV6, 8 and 9 and intraneuronal persistence of viral particles. Hum. Gene. Ther. 24, 613-629. doi: 10.1089/hum. 2012.174.
31. Lundberg, C., Bjorklund, T., Carlsson, T., Jakobsson, J., Hantraye, P., Deglon, N., et al. (2008). Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr. Gene Ther. 8, 461-473. doi: 10. 2174/156652308786847996.
32. Marks, W. J. Jr., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., et al. (2010). Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164-1172. doi: 10. 1016/S1474-4422(10)70254-4.
33. Marks, W. J. Jr., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 7, 400-408. doi: 10.1016/s1474-4422(08)70065-6.
34. Martinez, G., Vidal, R. L., Mardones, P., Serrano, F. G., Ardiles, A. O., Wirth, C., et al. (2016). Regulation ofmemoryformation bythe transcription factor XBP1. Cell Rep. 14, 1382-1394. doi: 10.1016/j.celrep.2016.01.028.
35. Mazzulli, J. R., Xu, Y. H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., et al. (2011). Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52. doi: 10. 1016/j.cell.2011.06.001.
36. Mazzulli, J. R., Zunke, F., Tsunemi, T., Toker, N. J., Jeon, S., Burbulla, L. F., et al. (2016). Activation of p-glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson’s patient midbrain neurons. J. Neurosci. 36, 7693-7706. doi: 10.1523/JNEUROSCI.0628-16.2016.
37. Mercado, G., Valdés, P., and Hetz, C. (2013). An ERcentric view of Parkinson’s disease. Trends Mol. Med. 19, 165-175. doi: 10.1016/j.molmed.2012.12.005.
38. Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., et al. (1998). Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51, 890-892. doi: 10. 1212/wnl.51.3.890.
39. Narendra, D., Tanaka, A., Suen, D. F., and Youle, R. J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795-803. doi: 10.1083/jcb.200809125.
40. Neumann, J., Bras, J., Deas, E., O’Sullivan, S. S., Parkkinen, L., Lachmann, R. H., et al. (2009). Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132, 1783-1794. doi: 10.1093/brain/ awp044.
41. Oh, S. M., Chang, M. Y., Song, J. J., Rhee, Y. H., Joe, E. H., Lee, H. S., et al. (2015). Combined Nurr1 and Foxa2 roles in the therapyofParkinson’s disease. EMBO Mol. Med. 7, 510-525. doi: 10.15252/emmm.201404610.
42. Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., et al. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383, 1138-1146. doi: 10.1016/S0140-6736(13)61939-X.
43. Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., et al. (2006). Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157-1161. doi: 10.1038/nature04788.
44. Petrova, P., Raibekas, A., Pevsner, J., Vigo, N., Anafi, M., Moore, M. K., et al. (2003). MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 20, 173-188. doi: 10.1385/jmn:20:2:173.
45. Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hallett, P., et al. (2015a). Progressive decline of glucocerebrosidase in aging and Parkinson’s disease. Ann. Clin. Transl. Neurol. 2, 433-438. doi: 10.1002/acn3.177.
46. Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hayes, M. A., et al. (2015b). Glucocerebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons. Neurobiol. Dis. 82, 495-503. doi: 10.1016/j.nbd.2015.09.009.
47. Rudow, G., O’Brien, R., Savonenko, A. V., Resnick, S. M., Zonderman, A. B., Pletnikova, O., et al. (2008). Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol. 115, 461-470. doi: 10. 1007/s00401-008-0352-8.
48. Sado, M., Yamasaki, Y., Iwanaga, T., Onaka, Y., Ibuki, T., Nishihara, S., et al. (2009). Protective effect against Parkinson’s disease-related insults through the activation of XBP1. Brain Res. 1257, 16-24. doi: 10.1016/j.brainres.2008. 11.104.
49. Salganik, M., Sergeyev, V. G., Shinde, V., Meyers, C. A., Gorbatyuk, M. S., Lin, J. H., et al. (2015). The loss ofglucose-regulated protein 78 (GRP78) during normal agingor from siRNA knockdown augments human α-synuclein (a-syn) toxicity to rat nigral neurons. Neurobiol Aging 36, 2213-2223. doi: 10.1016/j. neurobiolaging.2015.02.018.
50. Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., et al. (2009). A gene network regulating lysosomal biogenesis and function. Science 325, 473-477. doi: 10.1126/science.1174447.
51. Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., et al. (2011). PARIS (ZNF746) repression of PGC-1 a contributes to neurodegeneration in Parkinson’s disease. Cell 144, 689-702. doi: 10.1016/j.cell.2011.02.010.
52. Silva, R. M., Ries, V., Oo, T. F., Yarygina, O., Jackson-Lewis, V., Ryu, E. J., et al. (2005). CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J. Neurochem. 95, 974-986. doi: 10.1111/j.1471-4159.2005. 03428.x.
53. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jager, S., et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408. doi: 10.1016/j.cell.2006.09.024.
54. Valdés, P., Mercado, G., Vidal, R. L., Molina, C., Parsons, G., Court, F. A., et al. (2014). Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc. Natl. Acad. Sci. USA111, 6804-6809. doi: 10.1073/pnas.1321845111.
55. Van Rompuy, A. S., Lobbestael, E., Van der Perren, A., Van den Haute, C., and Baekelandt, V. (2014). Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration. J. Neuropathol. Exp. Neurol. 73, 159-174. doi: 10.1097/NEN.0000000000000039.
56. Walter, P., and Ron, D. (2011). The unfolded protein response: from stress pathway to homeostatic regulation. Science 334, 1081-1086. doi: 10. 1126/science.1209038.
57. Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., et al. (2015). Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann. Neurol. 78, 248-257. doi: 10.1002/ana.24436.
58. Yasuda, T., Miyachi, S., Kitagawa, R., Wada, K., Nihira, T., Ren, Y. R., et al. (2007). Neuronal specificity of α-synuclein toxicity and effect of Parkin co-expression in primates. Neuroscience 144, 743-753. doi: 10.1016/j.neuroscience.2006.09. 052.
59. Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., et al. (2010). PGC-1 α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl. Med. 2:52ra73. doi: 10.1126/scitranslmed. 3001059.